Download PDF
Thromb Haemost 2006; 96(01): 84-87
DOI: 10.1160/TH06-03-0183
Case Report
Schattauer GmbH

Rituximab in the treatment of acquired factor VIII inhibitors

Adedayo A. Onitilo
1   Department of Hematology/Oncology, Marshfield Clinic-Weston Center, Weston, Wisconsin, USA
,
Amy Skorupa
2   Hematology/Oncology Division, South Carolina, USA
,
Asheesh Lal
5   Hematology/Oncology, Lexington Medical Center, West Columbia, South Carolina, USA
,
Elizabeth Ronish
3   Department of Internal Medicine, South Carolina, USA
,
Richard J. Mercier
6   Department of Hematology/ Oncology, Marshfield Clinic, Marshfield, Wisconsin, USA
,
Rezwan Islam
1   Department of Hematology/Oncology, Marshfield Clinic-Weston Center, Weston, Wisconsin, USA
,
John Lazarchick
4   Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina, USA
› Author Affiliations
Further Information

Publication History

Received 17 May 2006

Accepted after resubmission 08 June 2006

Publication Date:
29 November 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Delgado J, Jimenez-Yuste V, Hernandez-Navarro F. et al. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003; 121: 21-35.
    CrossrefPubMedGoogle Scholar
  • 2 Michiels JJ. Acquired hemophilia A in women postpartum: clinical manifestations, diagnosis, and treatment. Clin Appl Thromb Hemost 2000; 06: 82-6.
    CrossrefPubMedGoogle Scholar
  • 3 Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost 1981; 45: 200-3.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Green D, Rademaker AW, Briet E. A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost 1993; 70: 753-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Schulman S, Langevitz P, Livneh A. et al. Cyclosporine therapy for acquired factor VIII inhibitor in a patient with systemic lupus erythematosus. Thromb Haemost 1996; 76: 344-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Sultan Y, Kazatchkine MD, Maisonneuve P. et al. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984; 02: 765-8.
    PubMedGoogle Scholar
  • 7 Lottenberg R, Kentro TB, Kitchens CS. Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med 1987; 147: 1077-81.
    CrossrefPubMedGoogle Scholar
  • 8 Wiestner A, Cho HJ, Asch AS. et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002; 100: 3426-8.
    CrossrefPubMedGoogle Scholar
  • 9 Stasi R, Brunetti M, Stipa E. et al. Selective Bcell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 103: 4424-8.
    CrossrefPubMedGoogle Scholar
  • 10 Kain S, Copeland TS, Leahy MF. Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab). Br J Haematol 2002; 119: 578.
    CrossrefPubMedGoogle Scholar
  • 11 Mathias M, Khair K, Hann I. et al. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia. Br J Haematol 2004; 125: 366-8.
    CrossrefPubMedGoogle Scholar
  • 12 Aggarwal A, Grewal R, Green RJ. et al. Rituximab for autoimmune haemophilia: a proposed treatment algorithm. Haemophilia 2005; 11: 13-9.
    CrossrefPubMedGoogle Scholar
  • 13 Rosendaal FR. High levels of factor VIII and venous thrombosis. Thromb Haemost 2000; 83: 1-2.
    Article in Thieme ConnectPubMedGoogle Scholar